Investigators have found that dasatinib, a drug commonly used to treat chronic myeloid leukemia, is strongly associated with kidney injury.
Sep 12, 2023
0
9
In an unexpected discovery, Georgetown University Medical Center researchers have identified what appears to be a significant vascular defect in patients with moderately severe Parkinson's disease. The finding could help ...
Nov 12, 2021
0
389
Dasatinib, a drug that often is used to treat certain types of leukemia, may have antidiabetic effects comparable to medications used to treat diabetes, and with more research may become a novel therapy for diabetic patients, ...
Nov 9, 2021
0
58
September is Leukemia and Lymphoma Awareness Month, which makes this a good time to learn about some of the most common types of these two diseases.
Sep 3, 2021
0
2
A new study led by researchers at the University of Kentucky Markey Cancer Center and UK Department of Pharmacology and Nutritional Sciences demonstrates the potential benefit of using an anti-leukemic drug nilotinib—most ...
Oct 30, 2020
2
66
Researchers have identified a second path to defeating chronic myelogenous leukemia, which tends to affect older adults, even in the face of resistance to existing drugs.
Sep 21, 2020
0
28
DGIST researchers have identified the causes of hypersensitivity accompanied by neurodevelopmental disorders such as autism-spectrum disorder (ASD). This is expected to make huge contributions to the early diagnosis of sensory-defective ...
Feb 14, 2020
0
40
Northwestern University and the Parkinson Study Group announced that the Nilotinib in Parkinson's Disease (NILO-PD) study showed that nilotinib, an FDA-approved treatment for chronic myelogenous leukemia being tested for ...
Dec 5, 2019
0
15
The introduction of the drug imatinib in 2001 revolutionized the treatment of a type of cancer called chronic myelogenous leukemia. In more than 80 percent of people with CML who received the drug, the disease went into complete ...
Oct 16, 2019
0
1021
Most patients with chronic myelogenous leukemia can be treated with tyrosine kinase inhibitors. These drugs are highly effective and lead to deep remission and prolonged survival. Yet quiescent leukemic stem cells persist ...
Mar 21, 2019
0
6
Chronic myelogenous (or myeloid) leukemia (CML), also known as chronic granulocytic leukemia (CGL), is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of predominantly myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell disorder in which proliferation of mature granulocytes (neutrophils, eosinophils, and basophils) and their precursors is the main finding. It is a type of myeloproliferative disease associated with a characteristic chromosomal translocation called the Philadelphia chromosome. CML is now largely treated with tyrosine kinase inhibitors (TKIs), such as imatinib, dasatinib, or nilotinib, which have led to dramatically improved survival rates since their introduction in the last decade.
This text uses material from Wikipedia licensed under CC BY-SA
